SPECT/CT study of bronchial deposition of inhaled particles. A human aerosol vaccination model against HPV. by Ilic, V. et al.
   
 
 
 
 
Serveur Acade´mique Lausannois SERVAL serval.unil.ch
Author Manuscript
Faculty of Biology and Medicine Publication
This paper has been peer-reviewed but does not include the final publisher
proof-corrections or journal pagination.
Published in final edited form as:
Title: SPECT/CT study of bronchial deposition of inhaled particles. A
human aerosol vaccination model against HPV.
Authors: Ilic V, Dunet V, Le Pape A, Buchs M, Kosinski M, Bischof
Delaloye A, Gerber S, Prior JO
Journal: Nuklearmedizin. Nuclear medicine
Year: 2016 Sep 26
Issue: 55
Volume: 5
Pages: 203-8
DOI: 10.3413/Nukmed-0811-16-03
In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains
an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.
SPECT/CT study of bronchial deposition of inhaled 
particles in a human aerosol vaccination  
model against HPV 
 
Vesna Ilic,1 Vincent Dunet,1 Alain Le Pape,2,3 Mikael Buchs,1 Marek 
Kosinski,1 Angelika Bischof Delaloye,1 Stefan Gerber,4 John O. Prior1 
 
1Department of Nuclear Medicine, Lausanne University Hospital, Lausanne, 
Switzerland; 2Research Center for Respiratory Diseases, INSERM 
U1100/EA 6305, François Rabelais University, Tours France; 3TAAM-
CIPA, UPS 44, CNRS, Orléans, France. 4Gynecology Practice, Fribourg 
Switzerland 
 
 
Running Head: SPECT/CT of bronchial deposition 
 
Character count for main text: 19’943 characters (<22’000) 
Character count for abstract:    1,777 characters (<1,800) 
 
Page 2 
ENGLISH SUMMARY 
Aims—Vaccination by aerosol inhalation can be used to efficiently deliver 
antigen against HPV to mucosal tissue, which is particularly useful in 
developing countries (simplicity of administration, costs, no need for cold 
chain). For optimal immunological response, vaccine particles should 
preferentially be delivered to proximal bronchial airways. We aimed at 
quantifying the deposition of inhaled particles in central airways and 
peripheral lung, and to assess administration biosafety.  
Methods—Twenty healthy volunteers (13W/7M, aged 24±4y) performed a 
10-min free-breathing inhalation of 99mTc-stannous chloride colloid aerosol 
(450 MBq) in a buffer solution without vaccinal particles using an 
ultrasonic nebulizer (mass median aerodynamic diameter 4.2 µm) and a 
double mask inside a biosafety cabinet dedicated to assess environmental 
particle release. SPECT/CT and whole-body planar scintigraphy were 
acquired to determine whole-body and regional C/P distribution ratio 
(central-to-peripheral pulmonary deposition counts). Using a phantom, 
SPECT sensitivity was calibrated to obtain absolute pulmonary activity 
deposited by inhalation. 
Results—All participants successfully performed the inhalation that was 
well tolerated (no change in pulmonary peak expiratory flow rate, P = 0.9). 
It was environmentally safe (no activity released in the biosafety filter.) 
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1.3±0.6% (range 0.4–2.6%) of the total nebulizer activity was deposited in 
the lungs with a C/P distribution ratio of 0.40±0.20 (range 0.15–1.14). 
Conclusion—Quantification and regional distribution of inhaled particles in 
an aerosolized vaccine model is possible using radioactive particles. This 
will allow optimizing deposition parameters and determining the particles 
charge for active-particles vaccination. 
 
 
KEYWORDS 
Aerosol inhalation; Pulmonary deposition; SPECT/CT; Tc-99m; Targeted 
vaccine delivery; HPV. 
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ZUSAMMENFASSUNG 
Ziel—Die Entwicklung von Aerosol-Impfstoffen mit welchen durch 
Inhalation Antigene gegen HPV effizient im Schleimhautgewebe 
aufgenommen werden, könnte in Entwicklungsländern besonders wichtig 
sein (einfach zu applizieren, kostengünstig, kein Bedarf an Kühlkette, usw.) 
Um eine optimale immunologische Wirkung zu erzielen, sollte der 
inhalierte Impfstoff präferentiell in den proximalen Bronchien abgeschieden 
werden. Das Ziel dieser Studie war es, die Verteilung inhalierter Partikel in 
den zentralen Bronchien und in peripheren Lungenabschnitten zu messen 
und deren Biosicherheit zu bestimmen.  
Methode—20 gesunde Versuchspersonen (13F/7M, 24±4Jahre) inhalierten 
während 10 Minuten unter Spontanatmung mittels eines Ultraschall-
verneblers (mittlerer aerodynamischer Tröpfchen-Durchmesser 4.2µm) ein 
Aerosol von 99mTc-Zinn-Chlorid (450 MBq) in einer Buffer Lösung ohne 
Impfstoff. Die Inhalation wurde mit einer doppelten Maske in einer speziell 
dafür entwickelten Abzugshaube durchgeführt und das Austreten von 
Aerosol-Partikeln in die Umwelt gemessen.  
Die Ganzkörper Verteilung und der regionale C/P Verteilungskoeffizient 
(Quotient zentrale über periphere Lungenaktivität) wurden mittels der 
SPECT/CT und einer Ganzkörper-Szintigraphie bestimmt. Die SPECT 
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Empfindlichkeit wurde mittels eines Phantoms kalibriert, um die absolute 
inhalierte Aktivität in der Lunge zu bestimmen. 
Ergebnisse—Die Inhalation wurde von allen Studienteilnehmern vollendet 
und gut vertragen (Peak Flow unverändert, P=0.9). Der Biosicherheitsfilter 
war frei von Radioaktivität. 1.3±0.6% (0.4–2.6%) der Gesamtaktivität des 
Verneblers wurde in den Lungen gemessen, mit einem C/P 
Verteilungsquotienten von 0.40±0.20 (0.15–1.14). 
Schlussfolgerung—Die Aufnahme und regionale Verteilung inhalierter 
Partikel können in einem Aerosol-Impf-Modell mittels radioaktiv markierter 
Partikel quantitativ bestimmte werden und so zur Optimierung der 
Parameter beitragen, die für Verteilung und Beladung von aktiven 
Impfstoff-Partikeln von Bedeutung sind.  
  
SCHLÜSSELWÖRTER 
  
Aerosol Inhalation; Atemwegsabscheidung; SPECT/CT; Tc-99m; Gezielte 
Impfstoff Anwendung; HPV 
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INTRODUCTION 
Vaccines constitute one of the most cost-effective preventive measures 
against illness and death from infectious disease [23]. Each year, five 
million people die worldwide from mucosally transmitted diseases that 
might be prevented by vaccines [8]. Cervical cancer is the second most 
common cancer in women in the world, the most common in Africa and the 
leading cause of cancer deaths in developing countries [4]. Vaccines against 
the leading HPV oncogenic types 16 and 18 are available with efficacy 
exceeding 95% in HPV-uninfected women [37]. However, efficient 
vaccination programs are difficult to implement in developing countries 
mainly because of currently prohibitive costs. 
Despite the unprecedented medical success of vaccination, 
traditional application routes (intramuscular or subcutaneous) are not 
without limitations. In the context of mass vaccination campaigns in 
developing countries, needle-free vaccination can increase compliance 
(reduced local pain and side effects) and decrease overall costs (no need for 
needle disposal, etc.) Specific vaccine formulations abolish the need for a 
“cold chain” (specific equipment, and procedures to maintain vaccine at low 
temperatures until administration) [19,24,28] and aerosol immunization is 
such an alternative. This is offering many advantages: ease of application by 
paramedical personnel, lesser invasiveness favouring acceptance, reduced 
risk of cross-contamination by blood-born infectious agents, diminished 
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medical waste, and lower costs thanks to the use of multidose vials, among 
others [2,21]. Moreover, aerosol vaccination may induce better 
immunogenicity than conventional subcutaneous injections [8] because 
mucosal immune response might induce broader protection due to the 
production of IgA in addition to systemic IgG antibodies [30,39]. 
Nuclear medicine is a unique resource for the translational research 
about therapies delivered as aerosols. Indeed, for both research and 
development SPECT or PET of aerosol lung deposition is the most relevant 
strategy to pre-clinically assess the actual dose delivered to the target area 
[7,9,15]. At the time of translation to clinical trials, lung deposition imaging 
allows to optimize aerosol delivery to the target for immunization (central 
lung) while minimizing potential side effects due to deposition in less 
effective area (peripheral lung). 
In a preclinical validation study in non-human primates, Corbett et 
al. [8] showed that aerosol-delivered poxvirus-based vaccination was safe, 
feasible, and immunogenic. The next step towards clinical implementation 
consists in validating this aerosol vaccination in humans. However, before 
dose escalation and safety analysis of side effects, more information needs 
to be collected about vaccinal particle charge and lung distribution during 
the face-mask aerosol nebulization [39]. Thus, the aims of our study were: 
(1) to assess the fraction of the nebulized particles delivered to the lungs to 
decide about the future viral charge; (2) to demonstrate a privileged 
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deposition of aerosolized particles into the central part of the lungs to elicit 
optimal immunological response, while limiting the alveolar exposure (not 
essential to proper immunization) and potential inflammation; and (3) to 
verify administration safety by quantifying environmental particle release. 
 
 
METHODS 
Study population 
Healthy volunteers were prospectively recruited by advertisement at the 
Lausanne University Hospital, Switzerland. Before inclusion, they 
underwent history taking (personal medical history including pulmonary 
disease, infectious disease, smoking, asthma and chronic obstructive 
pulmonary disease) and a physical examination. Peak expiratory flow rate 
(PEFR) was measured immediately before and after inhalation as a simple 
surrogate for asthma detection and to detect any subclinical change due to 
the aerosol-induced broncho-constrictive reaction. Women of childbearing 
age underwent a pregnancy test; a negative result was required before 
inclusion. The Local Ethic Committee, the Swiss Federal Office of Public 
Health and Swissmedic approved the study protocol and participants signed 
a written informed consent form. Participants received a total effective dose 
of 1.9 mSv (1.0 mSv from the radiotracer and 0.9 mSv for the low-
dose/slow-rotating CT) [36]. The radiation effective dose was obtained by 
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assuming that a maximum of 17% of the nebulized activity would be 
distributed in the patient based on a preclinical study [26] and an effective 
dose ED of 0.014 mSv/MBq computed from known organ distribution of 
nanocolloid aerosol (Venticoll™, GE Healthcare Srl, Milano, Italy) and 
ICRP 60 tissue weighting factors. 
 
Radiolabeling of particles and nebulization procedure 
The deposition procedure used non-viral, inert stannous chloride particles 
(MTcK-2, Polatom, Otwork-Świerk, Poland) labeled with 99mTc, with >90% 
of particles sized within 459–1110 nm (peaking at 788 nm) dispersed in a 4-
mL buffer solution of identical physical and chemical characteristics as the 
future vaccine but without immunogenic, sub-micrometric particles (Tris 
buffer 1.2g/L, saccharose 50g/L, Na glutamate 1.87g/L, NaCl 2.9 g/L, 
titrated with 5N HCl for pH 8.0). As previously described [26], aerosol 
generated from such a formulation exhibits the same granulometry and lung 
deposition pattern as the vaccine due to the low protein content. Labeling 
was performed according to the manufacturer instructions [34]. Preliminary 
measurements were conducted to verify labeling and particle size stability in 
the buffer solution (pH 8) during nebulization (data not shown).  
An ultrasonic nebulizer (Atomisor Megahertz AMGH, La Diffusion 
Technique, St-Etienne, France) was used to create aerosol from radiolabeled 
solution. Using a nebulization power set at 10/10, a 4.2 µm mass median 
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aerodynamic diameter (MMAD) aerosol was generated to favour central 
pulmonary distribution with care to prevent any temperature increase during 
sonication. To further privilege central pulmonary distribution of the 
aerosol, we chose active inhalation with disconnected internal ventilator and 
set tubing lengths 1 and 2 to get 75- and 300-ml buffer volumes, 
respectively (Figure 1A). For the inhalation process, the subject was placed 
in front of a biosafety cabinet containing a class-E12 HEPA filter, and 
equipped with a Double Mask system (Medicvent, Umeå, Sweden). The soft 
inner mask was connected to the nebulizer chamber and the hard outer mask 
evacuation outlet was connected to the biosafety cabinet aspiration through 
a separate HEPA filter to trap any aerosol particle escaping from the inner 
mask. The participants were instructed to freely inhale the nebulized aerosol 
in a controlled and reproducible tidal breathing manner for 10 minutes [27]. 
Residual activity in the nebulizer reservoir and tubing system was measured 
before and after the aerosol delivery. The activity released in the 
environment from the nebulization procedure was aspirated through the 
biosafety cabinet HEPA filter, whose activity was measured distant from the 
participant outside the administration room. 
 
Imaging acquisition and processing 
Twenty minutes after inhalation every participant underwent a SPECT/CT 
acquisition (Hawkeye IV, GE Healthcare, Milwaukee, MI) using an energy 
Page 12 
window 140 keV±20%, 60 projections of 8 sec, a 128x128 matrix, and CT 
acquisition parameters: 140kV, 2.5mA, helical, pitch 1.5, slice thickness 
5mm. Participants also underwent a whole-body planar scintigraphy in both 
anterior and posterior view 50 min post inhalation (scan velocity 10cm/min, 
256×1024 pixel).  
Raw data were processed on a dedicated workstation (Xeleris 3, GE 
Healthcare, Milwaukee, MI) by two experienced nuclear medicine 
physicians, in consensus. SPECT/CT images were reconstructed using 2D-
OSEM (10th-order Butterworth, 0.5-cycle/cm cut-off frequency). Regions of 
interest (ROI) were drawn on whole-body anterior and posterior images 
around each lung and for the whole-body; counts were computed using 
geometrical mean. On tomographic images, volumes of interest (VOI) were 
drawn following anatomical boundaries provided by CT on separate 
transaxial slices centered on the hilum for 1-st order bronchi and applied to 
the reconstructed SPECT dataset. This allowed to separate central particle 
deposition (from carina to lobar bronchus division) from peripheral 
deposition (beyond lobar bronchus division) (Figure 3 A) and to compute 
the central-peripheral deposition ratio C/P = COUNTScentral / 
COUNTSperipheral. A semi-quantitative analysis to compute a scintigraphic 
C/P index was also performed to quantify the uptake in central bronchi as 
compared to pulmonary parenchyma on the SPECT transaxial slices using a 
5-point Likert scale: C/P index = grade 0: no difference; grade 1: 
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questionable difference; grade 2: faint difference; grade 3: marked 
difference; grade 4: very strong difference. 
For quantifying total pulmonary particle deposition TPD, the 
sensitivity of SPECT/CT was calibrated using a 200-mL reference phantom 
containing 5MBq of 99mTc-pertechnetate imaged using the same SPECT 
acquisition and reconstruction parameters. This allowed computing the 
activity deposited in the lung volume from the total counts. The percentage 
of nebulized activity deposited in the lungs was then computed as TPD (%) 
= 100·COUNTSlungs / COUNTSstandard · 5 (MBq) / Activitynebulizer (MBq). 
Then, the absolute central pulmonary deposition CPD can be derived as 
CPD = TPD · [C/P] / (1 + [C/P]). All measured activities were corrected for 
the physical half-life of 99mTc. 
 
Statistical analysis 
Continuous variables are presented as mean±SD or as median and 25th to 
75th percentile interquartile range (IQR), and categorical variables are 
presented as number and percentage. We used non-parametric Wilcoxon 
rank sum test to compare continuous variables before and after the exam as 
well as to compare variables according to gender and smoking status. 
Association between variables was assessed using non-parametric Spearman 
correlation coefficient (ρ). Statistical analyses were performed with Stata 
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12.1 software (Stata Corp., College Station, TX) and a P-value <0.05 was 
considered as statistically significant. 
 
 
RESULTS 
Population 
Twenty-one healthy volunteers were enrolled and complete data were 
available in twenty participants (13 women, 7 men) aged 24±4 years. None 
had history of asthma or any other chronic or recent pulmonary condition; 5 
were smokers (25%). Pulmonary auscultation was unremarkable in all 
participants and peak expiratory flow rate was within normal range for age 
and sex (Table 1). 
 
Inhalation and procedure safety 
The 10.0-min nebulization could be performed safely in all participants with 
an activity of 430±20 MBq of 99mTc-colloid introduced in the nebulizer 
chamber. No participant experienced dyspnea during or after inhalation. No 
unexpected side effects or coughing were observed. Peak expiratory flow 
rate at the end of the study was identical to baseline (P = 0.9), also in 
subgroup analyses by gender and smoking status (Tab. 1). As expected, 
PEFR was significantly related to participants’ gender (–28% in women), 
height (ρ =0.78, P=0.0002) and body surface area (ρ =0.69, P=0.001). 
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The nebulization was also safe for the environment; no activity was 
released from the nebulization system or from the double mask in the 
biosafety cabinet HEPA filter. At the end of the inhalation, the nebulization 
system contained >90% of the activity, with the largest activity in the 
nebulization chamber (Fig. 1A and 1B). 
 
Inhaled particle distribution 
Whole-body scans revealed that inhaled particles were mainly localized in 
respiratory and digestive tracts, i.e. the mouth/oropharynx (N = 20), 
esophagus (N = 9), stomach (N = 17) and bowel (N = 13) due to saliva 
swallowing (Figure 1C). Of note, minimal activity could be seen in the 
bladder (N = 2, different than the one of Figure 1) and no activity was seen 
in the liver, spleen, kidney, thyroid or bone marrow.  
On planar scintigraphy, lung activity represented 40±9% of the total 
whole-body activity. There was no difference according to gender (women 
38±8% vs. men 43±11%, P=0.4) or to smoking status (non-smokers 
39±10% vs. smokers 43±6%, P = 0.2). On SPECT images, 54±4% particles 
were localized in the right lung and 46±4% in the left lung (P < 0.0001). 
This relative distribution was neither influenced by gender (P = 0.7) nor by 
smoking status (P = 0.6). There was also no significant difference between 
upper, middle and lower third of lung fields (P > 0.6).  
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Total pulmonary deposition, TPD was 1.3±0.6% (range 0.4–2.6%) 
of the total activity initially present in the nebulizer (Fig. 2). Residual 
inhaled particles were also seen on SPECT/CT in the trachea (N = 13) and 
on the skin (N = 9) due to salivary contamination from the mouth after 
inhalation. There was no significant difference between men and women 
(1.4±0.7% vs. 1.2±0.6%, P = 0.9) or between smokers and non-smokers 
(1.4±0.7% vs. 1.2±0.6%, P = 0.7). 
 
Regional lung distribution of inhaled particles 
SPECT/CT showed a central to peripheral deposition ratio C/P of 0.4±0.2 
(range 0.15–1.14) and a central pulmonary deposition CPD of 0.3±0.3% 
(range 0.1–1.4) (Fig. 2). An example is illustrated in Fig. 3, with VOI 
drawn for computing the central and peripheral activity. The C/P ratio was 
not affected by the smoking status (non-smokers 0.36±0.11 vs. smokers 
0.51±0.36, P = 0.6), but tended to be higher for women than men 
(0.46±0.22 vs. 0.30±0.11, P = 0.06). Of note, C/P ratio was significantly 
correlated with PEFR (ρ = –0.58, P = 0.01).  
The semi-quantitative C/P index showed a favourable central 
distribution with 11/20 (55%) of the participants showing a marked or very 
strong uptake and 15/20 (75%) showing a higher uptake in central regions 
than in parenchyma (grade 2 or above) (Fig. 4). 
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DISCUSSION 
Thanks to the use of scintigraphic imaging to optimize the deposition 
within the central lung, preclinical studies of aerosol administration 
poxvirus-based vaccines in non-human primates have led to a safe and 
long-lasting immune response [8,26]. Here, we performed a proof-of-
concept study in volunteers to assess the feasibility of aerosol 
nebulization, including the basic safety profile of non-vaccinal buffer 
solution at the individual and environmental level, and to quantify 
regional distribution.  Our results demonstrate that quantification of the 
regional distribution of radiolabeled aerosols in a human vaccine model 
without immunogenic particles is feasible. Moreover, the administration 
is safe for the participants and the environment. These results are 
encouraging for future vaccine application trials in humans, where the full 
safety profile and immune response will be assessed. 
Within the lung, several factors may influence the site of particle 
deposition, the size being one of the most important [18]. Particle sizes of 
4–5µm, such as the one produced in our study are thought to be optimal for 
a central deposition of an aerosol in the lungs [5]. The central lung is 
considered as the target area to elicit optimal immunological response 
[1,3,8,29,33]. The human upper airway mucosa contains a dense network of 
antigen-presenting cells throughout the nasal cavity, trachea, and lungs 
ready to initiate immune response when in contact with a microbial burden 
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[20]. During inspiration, larger particles will be deposited merely in the 
tubing system and smaller ones in the peripheral part of the lung [2,6,10].  
Planar gamma camera scintigraphy is well established for measuring 
deposition of radioaerosols [11,38]. SPECT /CT provides 3-dimensional, 
detailed information and offers a superior assessment of aerosol deposition 
[13,14,16]. In addition, we performed CT-based attenuation corrections of 
the SPECT images and used a calibration factor derived from a phantom to 
more accurately assess the activity deposited in target regions [27]. Our 
results support the feasibility of aerosol delivery of vaccines with preferred 
central lung distribution, in agreement with previous results in a series of 8 
non-human primates [8].  
The efficacy of inhaled drugs, whether given for treatment of lung 
disease [17,25,32,35] or to achieve an effect in some other part of the body, 
depends on drug deposition in the lungs. Our results with mean lung 
deposition TPD of 1.3±0.6% of the total nebulized activity were within 
range of values observed in the preclinical non-human primate study 
(3.6±1.1% and 1.8±0.5% for two different strains of poxvirus-based 
vaccine) [8]. Although this figure may seem low, it was sufficient to elicit 
durable vaccine immune response [8]. Similarly, our central-to-peripheral 
deposition ratio reached 0.4±0.2, close to the non-human primate 
preclinical values (C/P = 0.75 in average) [8] and is in agreement with our 
previsions in order to limit exposure of alveoli to vaccinal proteins 
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considering a potential risk of alveolitis. It is true that ultrafine aerosol-
like deposition can reach up to 30% in a single-breath, but with a clearly 
alveolar distribution, which is not what is needed for the same reason 
(eventual risk of alveolitis). For the first clinical studies, these safety 
considerations have oriented our choice on this particular ultrasonic 
nebulizer despite a relatively low predicted efficiency for delivering the 
aerosol to the central airways. Following this modelization study, this 
device will allow to precisely deliver escalating doses for the assessment 
of both efficacy and safety of the vaccine. 
A few limitations to our study need to be mentioned. This study 
was performed in healthy participants. However, in patients with airway 
disease, aerosol deposition can be different, namely with a more pronounced 
central deposition and a potentially faster washout of centrally deposited 
aerosols by mucociliary clearance or cough reflex [12]. However, this 
should not be a major problem in the proposed HPV vaccine model, as 
potential subjects would be young, non-HPV-exposed and devoid of lung 
disease. It is also worth mentioning that non-human primates were pre-
treated with atropine not only to reduce salivation, but also to get transient 
inhibition of the bronchial mucociliary clearance and favour antigen 
presentation; thus, the effect of mucociliary clearance or its transient 
inhibition need obviously to be specifically studied. This was not done in 
this study on volunteers and could have influenced the results. Moreover, 
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non-human primate results were also developed using planar scintigraphy 
and there are known differences between regional pulmonary depositions 
measured on 2-D planar scans and 3-D SPECT [14]. Finally, the 
assessment of nebulized particles could also be performed by PET with 
several advantages over SPECT (absolute quantitation without the need of 
a calibration standard, shorter isotope half-life) [31] but the labelling of 
aerosols with positron emitters remains challenging. 13NH2 has been 
employed to image saline-based aerosols but requires an on-site 
cyclotron[40]. Of note, the availability of 68Ge/68Ga generators may 
facilitate the use of PET in aerosol deposition research in the future with 
the possibility to directly use 68Ga instead of 99mTc to label kit-based 
radiopharmaceuticals [22].  
In conclusion, we demonstrated a feasible and safe method for 
aerosol delivery in humans of non-viral inert particles with identical 
physical and chemical characteristics as the future vaccine. Our study 
provides a bridge between in vivo preclinical testing and clinical trials, 
allowing the latter to be planned with increased confidence. The present 
work emphasizes the unique contribution of nuclear imaging in translational 
research for pulmonary delivery of active formulations administered as 
aerosols. Further studies will be needed to determine the optimal viral 
charge needed to guarantee the appropriate dose of active particles 
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deposited in the immunogenic central area and assess the immune response 
of aerosol vaccine.  
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FIGURES LEGENDS 
Fig. 1. Distribution of the radiolabelled particles after nebulization. (A) 
Nebulization system (f = filter, m = mask; nc = nebulization chamber; 1 = 
75-mL tubing; 2 = 300-mL tubing; *connected together during operation). 
(B) Corresponding planar scintigraphy of nebulization system. (C). Anterior 
and posterior whole-body planar scintigraphy showing particle distribution 
in the lung and mouth, oropharynx, trachea and stomach (s), but not in the 
thyroid, kidney, bladder, liver or spleen. 
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 Fig. 2. Boxplot of the total pulmonary deposition (TPD), central pulmonary 
deposition (CPD) and central-to-peripheral distribution ratio (C/P) (N = 20). 
Boxes represent the limits of the 1st and 3rd quartiles, as well as the median; 
numbers represent the mean [95%CI] 
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Fig. 3. SPECT/CT imaging of particles deposition in the lung. (A) SPECT 
(first row) and SPECT/CT fusion (second row) images showing excellent 
central deposition. (B) Maximum intensity SPECT projection in anterior 
view. (C) Three-dimensional image rendering fusion of the airways on CT 
and SPECT activity showing central bronchial accumulation of inhaled 
particles.  
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Fig. 4. Scintigraphic index of central/peripheral distribution of inhaled 
particles. This histogram shows the best side’s uptake in central bronchi as 
compared to pulmonary parenchyma uptake on SPECT with an example of 
anterior view of the maximum intensity projection image for each class 
(grade 0 = no difference; grade 1 = doubtful difference; grade 2 = faint 
difference; grade 3 = marked difference; grade 4= very strong difference). 
In total, 75% of the participants had a central/peripheral index of grade 2 or 
above (C/P ratio grade 2–4: 0.44±0.21 vs. grade-0–1: 0.22±0.12, P=0.02).  
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TABLES 
Table 1. Peak expiratory flow rate at baseline and after inhalation (N=20) 
Characteristics Baseline After inhalation P-value 
Peak expiratory flow 
rate [L/s] 
8.1±1.7 8.0±1.3 0.9 
Gender:    
Women (N=13) 7.1±0.7 7.1±0.6 0.8 
Men (N=7)   9.8±1.2*   9.6±0.5* 0.6 
Smoking status:    
Non-smoker (N=15) 8.1±1.8 8.0±1.4 0.7 
Smoker (N=5)   8.1±1.4†   8.2±1.2† 1.0 
*Significant difference vs. women (P=0.0005 at baseline; P<0.0001 after 
inhalation); 
†No difference vs. non-smokers (P=0.9 at baseline; P<0.7 after inhalation). 
 
